Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D2 receptors

Journal of Pharmacology and Experimental Therapeutics

Volumn 291, Issue 1, 1999, Pages 409-415

  Volkow, Nora D ^a,b   Wang, Gene Jack ^a   Fowler, Joanna S ^a   Logan, Jean ^a   Gatley, S John ^a   Wong, Cristopher ^a   Hitzemann, Robert ^b   Pappas, Naomi R ^a  

^a BROOKHAVEN NATIONAL LABORATORY   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; METHYLPHENIDATE; PSYCHOSTIMULANT AGENT; RACLOPRIDE; RADIOLIGAND;

ADULT; ARTICLE; BINDING KINETICS; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG RECEPTOR BINDING; FEMALE; HUMAN; IMAGE ANALYSIS; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR OCCUPANCY; REINFORCEMENT; SELF REPORT;

ADULT; BRAIN; CENTRAL NERVOUS SYSTEM STIMULANTS; DOPAMINE; FEMALE; HUMANS; MALE; METHYLPHENIDATE; RECEPTORS, DOPAMINE D2; REINFORCEMENT (PSYCHOLOGY);

EID: 0032843942     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. American Psychiatric Association (1994) Diagnostic and Statistics Manual IV, 4th ed., American Psychiatric Association, Washington, DC.
2. Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC and Pickar D (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: Evidence from a novel positron emission tomography method. Pro Natl Acad Sci USA 94:2569-2574.
3. Caine SB (1998) Cocaine abuse: Hard knocks for the dopamine hypothesis? Nature Neurosci 1:90-92.
4. Crabbe, JC and Phillips TJ (1998) Genetics of alcohol and other abused drugs. Drug Alcohol Depend 51:61-71.
5. Dewey SL, Morgan AE, Ashby CR Jr, Horan B, Kushner SA, Logan J, Volkow ND, Fowler JS, Gardner EL and Brodie JD (1998) A novel strategy for the treatment of cocaine addiction. Synapse 30:119-129.
6. De Wit H and Wise RA (1977) Blockade of cocaine reinforcement in rate with the dopamine receptor blocker pimozide, but not with the noradrenergic blockers phentolamine or phenoxybenzamine. Can J Psychol 31:195-203.
7. Di Chiara G and Imperato A (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Nat Acad Sci USA 85:5274-5278.
8. Egilmez Y, Jung ME, Lane JD and Emmett-Oglesby MW (1995) Dopamine release during cocaine self administration: Effect of SCH23390. Brain Res 701:142-150.
9. Fischman MW and Foltin RW (1991) Utility of subjective-effects measurements in assessing abuse liability of drugs in humans. Br J Addict 86:1563-1570.
10. Gatley SJ, Pan D, Chen R, Chaturvedi G and Ding YS (1996) Affinities of methylphenidate derivatives for dopamine, norepinephrine and serotonin transporters. Life Sci 58:231-239.
11. Geter-Douglass B and Riley AL (1996) Dopamine D1/D2 antagonist combinations as antagonists of the discriminative stimulus effects of cocaine. Pharmacol Biochem Behav 54:439-451.
12. Gifford A, Gatley SJ and Ashby CR (1996) Endogenously released dopamine inhibits the binding of dopaminergic PET and SPECT ligands in superfused rat striatal slices. Synapse 22:232-238.
13. Giros B, Jaber M, Jones SR, Wightman RM and Caron MG (1996) Hypertocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature (Lond) 379:606-612.
14. Jones SR, Gainetdinov RR, Jaber M, Giros B, Wightman RM and Caron MG (1998) Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci USA 95:4029-4034.
15. Kirk RE (1990) Statistics: An Introduction. Holt, Rinehart, and Winston, Inc., Fort Worth, TX.
16. Kleber HD (1994) Our current approach to drug abuse-progress, problems, proposals. N Engl J Med 330:361-365.
17. Koob GF and Bloom FE (1988) Cellular and molecular mechanism of drug dependence. Science (Wash DC) 242:715-723.
18. Kreek MJ (1997) Goals and rationale for pharmacotherapeutic approach in treating cocaine dependence: Insights from basic and clinical research. NIDA Res Monogr 175:5-35.
19. Kuczenski R and Segal DS (1997) Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: Comparison with amphetamine. J Neurochem 68:2032-2037.
20. Laruelle M, Abi-Dargham A, van Dyck CH, Rosenblatt W, Zea-Ponce Y, Zoghbi SS, Baldwin RM, Charney DS, Hoffer PB, Kung HF and Innis RB (1995) SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med 36:1182-1190.
21. Laruelle M, D'Souza CD, Baldwin RM, Abi-Dargham A, Kanes SJ, Fingado CL, Seibyl JP, Zoghbi SS, Bowers MB, Jatlow P, Charney DS and Innis RB (1997a) Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology 17:162-174.
22. Laruelle M, Iyer RN, al-Tikriti MS, Zea-Ponce Y, Malison R, Zoghbi SS, Baldwin RM, Kung HF, Charney DS, Hoffer PB, Innis RB and Bradberry CW (1997b) Microdialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates. Synapse 26:1-14.
23. Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer D, MacGregor RR, Hitzemann R, Bendriem B, Gatley SJ and Christman DR (1990) Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(1)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10:740-747.
24. 11C] raclopride binding in the brain: Model simulations and kinetic analysis of PET data. J Cereb Blood Flow Metab 14:995-1010.
25. 3H]cocaine binding sites in caudate-putamen. J Pharmacol Exp Ther 261:131-141.
26. Maldonado R, Saiardi A, Valverde O, Samad TA, Roques BP and Borrelli E (1997) Absence of opiate rewarding effects in mice lacking dopamine D2 receptors. Nature (Lond) 388:586-589.
27. 11C]raclopride binding at high D2 receptor occupancy: A PET study in haloperidol-treated patients. Psychiatry Res 67:163-171.
28. O'Brien, CP (1997) A range of research-based pharmacotherapies for addiction. Science (Wash DC) 278:66-70.
29. Ohuoha DC, Maxwell JA, Thomson LE 3rd, Cadet JL and Rothman RB (1997) Effect of dopamine receptor antagonists on cocaine subjective effects: A naturalistic case study. J Subst Abuse Treat 14:249-258.
30. Parsons LH, Weiss F and Koob GF (1998) Serotonin1B receptor stimulation enhances cocaine reinforcement. J Neurosci 18:10078-10089.
31. Richardson NR, Smith AM and Roberts DC (1994) A single injection of either flupenthixol decanoate or haloperidol decanoate produces long-term changes in cocaine self-administration in rats. Drug Alcohol Depend 1:23-25.
32. Ritz MC, Lamb RJ, Goldberg SR and Kuhar MJ (1987) Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science (Wash DC) 237:1219-1223.
33. Rocha BA, Fumagalli F, Gainetdinov RR, Jones SR, Ator R, Giros B, Miller GW and Caron MG (1998a) Cocaine self-administration in dopamine-transporter knockout mice. Nature Neurosci 1:132-137.
34. Rocha BA, Scearce-Levie K, Lucas JJ, Hiroi N, Castanon N, Crabbe JC, Nestler EJ and Hen R (1998b) Increased vulnerability to cocaine in mice lacking the serotonin-1B receptor. Nature (Lond) 393:175-178.
35. Seeman P, Guan HC and Niznik HB (1989) Endogenous dopamine lowers the dopamine D2 receptor density as measured by 3H raclopride: Implications for positron emission tomography of the human brain. Synapse 3:96-97.
36. Self DW, Barnhart WJ, Lehman DA and Nestler EJ (1996) Opposite modulation of cocaine-seeking behavior by D1- and D2-like dopamine receptor agonists. Science (Wash DC) 271:1586-1589.
37. Sora I, Wichems C, Takahashi N, Li XF, Zeng Z, Revay R, Lesch KP, Murphy DL and Uhl GR (1998) Cocaine reward models: Conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc Natl Acad Sci USA 95:7699-7704.
38. Srinivas NR, Hubbard JW, Quinn D, Korchinski ED and Midha K (1991) Extensive and enantioselective presystemic metabolism of dl-threo-methylphenidate in humans. Prog Neuro-psychopharmacol Biol Psychiatry 15:213-220.
39. Strange P (1997) Biochemical characterization of dopamine receptors, in The Dopamine Receptors (Neve KA and Neve RL eds) pp 3-26, Humana Press, Totowa, NJ.
40. Villemagne VL, Rothman RB, Yokoi F, Rice KC, Matecka D, Dannals RF and Wong DF (1999) Doses of GBR12909 that suppress cocaine self-administration in non-human primates substantially occupy dopamine transporters as measured by [11C] WIN35,428 PET scans. Synapse 32:44-50.
41. Volkow ND, Ding Y-S, Fowler JS, Wang GJ, Logan J, Gatley SJ, Dewey SL, Ashby C, Lieberman J, Hitzemann R and Wolf AP (1995) Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in human brain. Arch Gen Psychiatry 52:456-463.
42. Volkow ND, Fowler JS, Gatley SJ, Dewey SL, Wang G-J, Logan J, Ding Y-S, Francescci D, Gifford A, Morgan A, Pappas N and King P (1998) Comparable changes in synaptic dopamine induced by methylphenidate and by cocaine in the baboon brain. Synapse 31:59-66.
43. 11C raclopride binding in the human brain. J Nucl Med 34:609-613.
44. Volkow ND, Wang G-J, Fischman MW, Foltin RW, Fowler JS, Abumrad NN, Vitkun S, Logan J, Gatley SJ, Pappas N, Hitzemann R and Shea K (1997a) Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature (Lond) 386:827-830.
45. Volkow ND, Wang G-J, Fowler JS, Fischman M, Foltin R, Abumrad NN, Gatley SJ, Logan J, Wong C, Gifford A, Hitzemann R and Pappas (1999) N Methylphenidate and cocaine have a similar in vivo potency to block dopamine transporters in the human brain. Life Sci 65:7-12.
46. Volkow ND, Wang G-J, Fowler JS, Gatley SJ, Logan J, Ding Y-S, Dewey SL, Hitzemann R, Gifford A and Pappas NR (1999) Blockade of striatal dopamine transporters by intravenous methylphenidate is not sufficient to induce self reports of "high." J Pharmacol Exp Ther 288:14-20.
47. Volkow ND, Wang G-J, Fowler JS, Logan J, Gatley SJ, Hitzemann R, Chen AD and Pappas N (1997b) Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. Nature (Lond) 386:830-833.
48. 11C]raclopride in the human brain. Synapse 16:255-262.
49. Volkow ND, Wang G-J, Gatley SJ, Fowler JS, Ding Y-S, Hitzemann R, Logan J, Wong C and Lieberman J (1996) Temporal relationships between the pharmacokinetics of methylphenidate in the human brain and its behavioral and cardiovascular effects. Psychopharmacology 123:26-33.
50. Wang G-J, Volkow ND, Fowler JS, Logan J, Pappas NR, Natusil N, Wong CT and Hitzemann RJ (1999) Reproducibility of repeated measures of endogenous dopamine competition with [C-11]raclopride in the human brain. J Nucl Medicine 40:1285-1291.
51. Wang G-J, Volkow ND, Hitzemann RJ, Wong C, Angrist B, Burr G, Pascani K, Pappas N, Lu A, Cooper T and Lieberman JA (1997) Behavioral and cardiovascular effects of intravenous methylphenidate in normal subjects and cocaine abusers. Eur Addict Res 3:49-54.
52. Woolverton WL (1986) Effects of a D1 and a D2 dopamine antagonist on the self-administration of cocaine and piribedil by rhesus monkeys. Pharmacol Biochem Behav 24:531-535.